Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens
详细信息 查看全文
- 作者：Yuji Takei ; Yoshifumi Takahashi ; Shizuo Machida ; Akiyo Taneichi ; Suzuyo Takahashi ; Tomomi Nagashima ; Hiroyuki Morisawa ; Yasushi Saga ; Shigeki Matsubara ; Hiroyuki Fujiwara
- 刊名：Journal of Obstetrics and Gynaecology Research
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：43
- 期：2
- 页码：358-364
- 全文大小：161.1KB
- ISSN：1447-0756
文摘
Gemcitabine is used not only as a second-line, but also as a third-line or higher regimen for taxane/platinum-resistant recurrent ovarian cancer. The purpose of this study was to clarify the response to and toxicity of gemcitabine for recurrent ovarian cancer according to the number of previous chemotherapy regimens.